Lifeward schedules March 12 meeting to vote on Oratech acquisition from Oramed; board to expand to 8

Lifeward Ltd.

EGM on March 12, 2026 to approve issuance of shares to Oramed as consideration for acquiring all of Oratech.
Upon closing, board to consist of 8 members: 3 from Lifeward, 3 from Oramed, and 2 external directors.
Oramed would hold at least 45% (potentially >49.99%) of voting power, triggering change-of-control rules.
Other proposals: election of external directors, increase in 2025 incentive plan shares, CEO equity grant, auditor reappointment.
Definitive proxy statement expected to be filed on or about February 9, 2026.

item 5.02item 5.07

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.